



Applying Evolving Targeted Therapy in Acute Myeloid Leukemia



Reference List

- Arog Pharmaceuticals, Inc. Study of crenolanib vs midostaurin following induction chemotherapy and consolidation therapy in newly diagnosed FLT3 mutated AML. ClinicalTrials.gov. Updated May 22, 2020. <https://clinicaltrials.gov/ct2/show/NCT03258931>
- Cancer Stat Facts: Leukemia- Acute Myeloid Leukemia (AML). In: Surveillance, Epidemiology, and End Results Program. Accessed February 23, 2023. <https://seer.cancer.gov/statfacts/html/amyl.html>
- DeAngelo DJ, Jonas BA, Liesveld JL, et al. Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. *Blood*. 2022;139(8):1135-1146.
- DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. *N Engl J Med*. 2020;383(7):617-629.
- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424-447.
- Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. *Blood*. 2016;127(1):53-61.
- Erba HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2023;401(10388):1571-1583.
- Ferrara F, Barosi G, Venditti A, et al. Consensus-based definition of unfit to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. *Leukemia*. 2013;27(5):997-999.
- Forma Therapeutics, Inc. Open-label study of FT-2102 with or without azacytidine or cytarabine in patients with AML or MDS with an IDH1 mutation. ClinicalTrials.gov. Updated August 9, 2023. <https://clinicaltrials.gov/ct2/show/NCT02719574>
- Gilead Sciences. Study of magrolimab versus placebo in combination with venetoclax and azacytidine in participants with acute myeloid leukemia (ENHANCE-3). ClinicalTrials.gov. Updated August 31, 2023. <https://clinicaltrials.gov/study/NCT05079230>
- GlycoMimetics Incorporated. Study to determine the efficacy of uproleselan (GMI-1271) in combination with chemotherapy to treat relapsed/refractory acute myeloid leukemia. ClinicalTrials.gov. Updated July 25, 2023. <https://clinicaltrials.gov/ct2/show/NCT03616470>
- Kayser S, Levis MJ. Updates on targeted therapies for acute myeloid leukaemia. *Br J Haematol*. 2022;196(2):316-328.
- Lai C, Doucette K, Norsworthy KS. Recent drug approvals for acute myeloid leukemia. *J Hematol Oncol*. 2019;12(1):100.
- Levis M, Perl AE. Gilteritinib: potent targeting of FLT3 mutations in AML. *Blood Adv*. 2020;4(6):1178-1191.
- Levis M. Midostaurin approved for FLT3-mutated AML. *Blood*. 2017;129(26):3403-3406.
- Mei M, Aldoss I, Marcucci G, Pullarkat V. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use. *Am J Hematol*. 2019;94(3):358-362.
- Mohile S, Dale W, Somerfield M, Hurria, A. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology Summary. *J Oncol Pract*. 2018;14(7):442-446.

Applying Evolving Targeted Therapy in Acute Myeloid Leukemia



Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in *IDH1*-mutated acute myeloid leukemia. *N Engl J Med*. 2022;386(16):1519-1531.

Norsworthy KJ, Ko CW, Lee JE, et al. FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. *Oncologist*. 2018;23(9):1103-1108.

Ritchie EK, Klepin HD, Storrick E, et al. Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. *Blood Adv*. 2022;6(12):3812-3820.

Servier. Study of AG-120 (ivosidenib) vs. placebo in combination with azacytidine in participants with previously untreated acute myeloid leukemia with an IDH1 mutation (AGILE). ClinicalTrials.gov. Updated July 12, 2023.

<https://clinicaltrials.gov/ct2/show/NCT03173248>

Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant *IDH2* relapsed or refractory acute myeloid leukemia. *Blood*. 2017;130(6):722-731.

Stichting Hemato-Oncologie voor Volwassenen Nederland. A study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndromes with excess blasts-2 with FLT3 mutations eligible for intensive chemotherapy (HOVON 156 AML). ClinicalTrials.gov. Updated June 15, 2023. <https://clinicaltrials.gov/ct2/show/NCT04027309>

Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. *N Engl J Med*. 2017;377(5):454-464.

Venclexta. [Prescribing information]. Updated June 15, 2022.

<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208573>.

Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial [published correction appears in *Lancet Haematol*. 2023 Jan;10(1):e9]. *Lancet Haematol*. 2023;10(1):e46-e58.